Navigating the Future of Compounding: Opportunities Beyond Semaglutide & Tirzepatide

White Paper
Navigating the Future of Compounding: Opportunities Beyond Semaglutide & Tirzepatide

Presented by Restore Health Consulting, LLC

Executive Summary

The compounding industry is undergoing a significant transformation. With the recent resolutions of the semaglutide and tirzepatide shortages, along with increased FDA scrutiny and legal challenges (such as the OFA vs. FDA tirzepatide case), many 503A and 503B facilities that relied on GLP-1 compounding are now at a crossroads. While some may see these changes as the end of an era, the reality is that compounding is evolving, and new opportunities are emerging for those willing to adapt.

This paper explores viable market opportunities for 503A compounding pharmacies and 503B outsourcing facilities, helping them pivot to sustainable, compliant, and high-demand formulations. It also outlines how Restore Health Consulting, LLC can assist businesses in navigating these shifts strategically.